Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine Safety and Efficacy in Healthy Malian Adults
NCT03510481Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sanaria PfSPZ Vaccine in malaria (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Local and Systemic Adverse Events in Year One at Year 1 and Number of Participants With Local and Systemic Adverse Events in Year Two at Year 2. Started May 2018; status: completed.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03510481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510481.